NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISOPTO CARPINE is a pilocarpine hydrochloride ophthalmic solution approved by the FDA in June 2010 for treating glaucoma and ocular hypertension. It is a cholinergic agonist that works by increasing aqueous humor outflow through the trabecular meshwork and ciliary muscle contraction. The drug is administered as eye drops.
LOE Approaching
As LOE approaches, the brand team is likely consolidating resources; expect smaller commercial footprint and focus on retention over expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ISOPTO CARPINE offers limited career growth given its approaching LOE and minimal linked job openings (0 current). Career mobility on this product is best suited for professionals developing expertise in managed decline, generic transition, or niche market retention rather than growth-phase skill-building.
Brand ManagerField Sales Representative
Worked on ISOPTO CARPINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.